associated with intensive animal farming. There remains a need for the treatment of pain in a subject and compositions for use therein.

Summary of the Invention

In one aspect, the present invention refers to use of progeny cells from culture of multiply-passaged cells from an adipose tissue-derived cell suspension and adipose tissue-derived cell secretions in the manufacture of a medicament for the treatment of a condition selected from the group consisting of an inflammatory disorder, a ligament injury and a tendon injury, or alleviating pain associated with an inflammatory disorder, a ligament injury or a tendon injury, in a mammalian subject, wherein said secretions comprise clarified and/or concentrated media from culture of adipose tissue-derived cells which have arisen as progeny cells or a cell line from prior culturing, and wherein said medicament is stored frozen under appropriate conditions and the medicament is suitable to be administered to the subject within two hours of thawing the composition.

Methods previously described for the treatment of inflammatory disorders using adipose tissue-derived cell suspensions and cell free compositions teach the administration of the composition or suspension to the afflicted area, such as by intra-articular injection in the case of an arthritic joint. Surprisingly, the inventor has now identified that direct administration of the therapeutic composition to the afflicted area is not required. The inventor has surprisingly identified that the remote delivery of a composition comprising secretions from an adipose tissue-derived cell suspension or of a composition comprising an adipose tissue-derived cell suspension, optionally comprising adipocytes, or of a combination thereof, can also be effective in the treatment of such conditions.

The inventors have surprisingly identified that frozen stem cells, such as mesenchymal stem cells, such as adipose tissue-derived stem cells, may be used as therapeutic agents in treatment of various conditions. Surprisingly such frozen cells may be used without the need for culturing the cells after retrieval from frozen storage. The inventors have also identified that storage of cells in the presence of cell-derived secretions improves the viability and proliferation potential of cryopreserved stem cells, includuding cells dervied from adipose tissue.

Accordingly, also described herein is a method of treating a condition selected from the group consisting of an inflammatory disorder, a ligament injury and a tendon injury, or alleviating pain associated with an inflammatory disorder, a ligament injury

or a tendon injury, in a subject, comprising administering to the subject a pharmaceutical composition which comprises (i) adipose tissue-derived cell secretions, or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes or (iii) a combination of (i) and (ii), wherein said administration to said subject is at a site remote from the site of said condition. In an example the subject is a mammalian subject. In an example the adipose tissue-derived cell suspension, optionally comprising adipocytes comprises aggregates of cells and or comprises pieces of adipose tissue. In an example the cell suspension comprises adipocytes. In an example the cell suspension is substantially free of adipocytes. In an example the adipose tissue-derived cell secretions comprises a carrier liquid selected from cell culture media and

distilled water. In an example an adipose tissue-derived cell suspension, optionally comprising adipocytes, or a combination of an adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, optionally comprising adipocytes comprises a carrier liquid being a cell culture medium, such as DMEM.

In an example the inflammatory disorder or condition is selected from the group consisting of osteoarthritis, stifle disease, wobblers, a tendon injury and a ligament injury. In an example the inflammatory disorder is atopic dermatitis. In an example the inflammatory disorder or condition is selected from the group consisting of rheumatoid arthritis, back pain, and multiple sclerosis. In an example the inflammatory disorder or condition is an immune driven disease. In an example the method comprises administration of adipose tissue-deerived cell secretions. In an example the method comprises administration of an adipose tissue-derived cell suspension. In an example the administration is subcutaneous administration. In an example the administration is intra-muscular administration. In an example the administration is in the rump, arm, or buttocks. In an example the administration is into the neck of the subject, such as the nape of the subject, such as the scruff of the neck when the subject is a dog or cat.

Also described herein is a method of treating a joint disease or condition in a subject, the method comprising administering to the subject a pharmaceutical composition which comprises (i) adipose tissue-derived cell secretions, or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of (i) and (ii), wherein said administration to said subject is at a site remote from the site of said condition. In an example the subject is a mammalian subject. In an example the adipose tissue-derived cell suspension, optionally comprising adipocytes, comprises aggregates of cells and or comprises pieces of adipose tissue. In an example the adipose tissue-derived cell secretions comprises a carrier liquid selected from cell culture media and distilled water. In an example an adipose tissue-derived cell suspension, optionally comprising adipocytes, or a combination of an adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, optionally comprising adipocytes, comprises a carrier liquid being a cell culture medium, such as DMEM. In an example the treatment comprises administering a pharmaceutical composition comprising an adipose tissue-derived cell suspension to said mammal by subcutaneous injection. In an example the subcutaneously administered cell suspension is substantially free of adipocytes. In an example the subcutaneously administered cell suspension comprises adipocytes.

In an example the mammalian subject is an equine, feline, canine, bovine or porcine animal. In an example the subject is a human. In an example the subject is poultry.

In an example the administration is subcutaneous administration. In an example the administration is intra-muscular administration. In an example the administration is in the rump, arm, or buttocks. In an example the administration is into the neck of the subject, such as the nape of the subject, such as the scruff of the neck when the subject is a dog or cat.

Also described herein is a method for the treatment or prevention of a disease in an intensively farmed animal, the method comprising administering to the animal a pharmaceutical composition which comprises (i) adipose tissue-derived cell secretions, or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, optionally comprising adipocytes, wherein said administration is by subcutaneous injection or intramuscular injection.

In an example the disease of an intensively farmed animal is an orthopeadic developmental disease. In an example the disease of an intensively farmed animal is selected from the group consisting of leg weakness, lameness, arthritis, developmental diseases and bacterial infection. In an example the developmental disease is osteochondrosis (OCD).

In an example the pharmaceutical composition is administered to an animal prior to the onset of clinical symptoms of the disease. In an example the intensively farmed animal is a pig and the pharmaceutical composition is administered prior to the onset of clinical symptoms of the orthopeadic developmental disease, such as osteochondrosis.

In an example the intensively farmed animal is selected from the group consisting of pigs, cattle, sheep, and poultry,

In an example the intensively farmed animal is a breeder female. In an example the intensively farmed animal is a pregnant female. In an example the animal is a pregnant sow. In an example the pregnant sow has clinical symptoms of osteochondrosis or arthritis.

In an example the administration is subcutaneous administration. In an example the administration is intra-muscular administration. In an example the administration is into the neck of the subject, such as the nape of the subject.

The following examples apply to all aspects of the disclosure herein, unless the context clearly indicates otherwise.

In an example the adipose tissue-derived cell secretions are prepared from an adipose tissue-derived cell suspension. In an example the adipose tissue-derived cell suspension is substantially free of adipocytes. In an example the adipose tissue-derived cell suspension further comprises adipocytes. In an example the adipose tissue-derived cell suspension comprises mature adipocytes. In an example the adipose tissue-derived cell secretions are prepared by culture of adipose tissue-derived cell suspension. In an example the adipose tissue-derived cell suspension is substantially free of adipocytes. In an example the adipose tissue-derived cell suspension further comprises adipocytes. In an example the adipose tissue-derived cell suspension, optionally comprising adipocytes comprises aggregates of cells and or comprises pieces of adipose tissue.

In an example the adipose tissue-derived cell suspension is prepared by a method that comprises removal of (i) part of the adipocyte content or (ii) substantially all of the adipocyte content during preparation of the adipose tissue-derived cell suspension.

In an example the adipose tissue-derived cell secretions is a concentrated preparation. In an example the concentrated preparation is concentrated in comparison to the cell secretions as initially harvested from the adipose tissue-derived cell suspensions or culture thereof. In an example the adipose tissue-derived cell secretions is a preparation concentrated by between about 2-fold and about 20-fold. In an example the adipose tissue-derived cell secretions is a preparation concentrated by about 10-fold.

In an example the adipose tissue-derived cell secretions is of bovine, canine, porcine or equine origin. In an example the adipose tissue-derived cell secretions is of human origin.

In an example, the adipose tissue-derived cell secretions is derived from adipose tissue autologous to the recipient subject or animal. In an example the adipose tissue-derived cell secretions is derived from adipose tissue allogeneic to the recipient subject or animal. In an example the adipose tissue-derived cell secretions is derived from adipose tissue xenogeneic to the recipient subject or animal.

In an example the adipose tissue-derived cell suspension, optionally comprising adipocytes, comprises mature adipocytes.

In an example the adipose tissue-derived cell suspension, optionally comprising adipocytes is of bovine, canine, porcine or equine origin. In an example the adipose tissue-derived cell suspension, optionally comprising adipocytes is derived from adipose tissue autologous to the recipient subject or animal. In an example the adipose tissue-derived cell suspension, optionally comprising adipocytes is derived from adipose tissue

allogeneic to the recipient subject or animal. In an example the adipose tissue-derived cell suspension, optionally comprising adipocytes is derived from adipose tissue xenogeneic to the recipient subject or animal.

In an example the adipose tissue-derived cell suspension, optionally comprising adipocytes is a cell suspension obtained by cell expansion in culture.

In an example the adipose tissue-derived cell secretions, or a pharmaceutical composition thereof are stored frozen prior to administration.

In an example the adipose tissue-derived cell suspension, optionally comprising adipocytes, or a pharmaceutical composition thereof are stored frozen prior to administration.

In an example the adipose tissue-derived cell secretions in combination with adipose tissue-derived cell suspension, optionally comprising adipocytes, or a pharmaceutical composition thereof is stored frozen prior to administration. In an example the cell secretions in said combination are a concentrated preparation. In an example the preparation is concentrated by between 2-fold and 20-fold in comparison to the secretions prior to concentration.

In an example the method further comprises (i) thawing frozen adipose tissue-derived cell secretions, or (ii) thawing frozen adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) thawing a frozen combination of adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iv) thawing a frozen pharmaceutical composition of any of (i), (ii) or (iii), prior to administration to the recipient subject or animal.

In an example the frozen secretions, cell suspension, combination thereof, or pharmaceutical composition thereof, is administered to the recipient subject or animal soon after thawing, such as within about 10 minutes after thawing, or within about 20 minutes after thawing, or within about 30 minutes after thawing or within about one hour of thawing or within about two hours of thawing.

In an example the method further comprises combining (i) a composition comprising adipose tissue-derived cell secretions and (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, prior to administering said combination to the recipient subject or animal. In an example said combining occurs within 2 hours before said administration. In an example one or both of said composition comprising adipose tissue-derived cell secretions and said adipose tissue-derived cell suspension, optionally comprising adipocytes, is stored frozen prior to said combining. In a further

example the composition comprising adipose tissue-derived cell secretions and said adipose tissue-derived cell suspension, optionally comprising adipocytes, are mixed together before the composition is frozen.

In an example the pharmaceutical composition is a veterinary composition and the subject is a non-human animal.

Also described herein is use of (i) adipose tissue-derived cell secretions, or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of (i) and (ii), for the preparation of a pharmaceutical composition for use in the treatment of a condition selected from the group consisting of an inflammatory disorder, a ligament injury and a tendon injury, or alleviating pain associated with an inflammatory disorder, a ligament injury or a tendon injury, in a mammalian subject, wherein the composition is suitable for administration to a site of said subject remote from the site of said condition.

In a fifth aspect there is provided use of (i) adipose tissue-derived cell secretions, or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of (i) and (ii), for the preparation of a pharmaceutical composition for use in the treatment of a joint disease or condition in a mammalian subject, wherein the composition is suitable for administration to a site of said subject remote from the site of said condition. In an example the adipose tissue-derived cell suspension, optionally comprising adipocytes, comprises aggregates of cells and or comprises pieces of adipose tissue. In an example the adipose tissue-derived cell suspension is substantially free of adipocytes. In an example the adipose tissue-derived cell suspension comprises adipocytes.

Also described herein is use of (i) adipose tissue-derived cell secretions, or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of (i) and (ii), for the preparation of a pharmaceutical composition for use in the treatment or prevention of disease in an intensively farmed animal, wherein the composition is suitable for subcutaneous injection or intramuscular injection.

Also described herein is a composition comprising (i) adipose tissue-derived cell secretions, or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of (i) and (ii), for treatment of a condition selected from the group consisting of an inflammatory disorder, a ligament injury and a tendon injury, or alleviating pain associated with an inflammatory disorder, a ligament injury or a tendon injury, wherein the composition is administered to a site on a subject remote from

the site afflicted by the condition. In an example the composition is an injectable composition. In an example the administration is by subcutaneous injection or intramuscular injection.

Also described herein is a composition comprising (i) adipose tissue-derived cell secretions, or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of (i) and (ii), for treatment of a joint disease or condition in a mammalian subject, wherein said composition is administered a site of said subject remote from the site of said condition. In an example the adipose tissue-derived cell suspension, optionally comprising adipocytes, comprises aggregates of cells and or comprises pieces of adipose tissue. In an example the adipose tissue-derived cell suspension is substantially free of adipocytes. In an example the adipose tissue-derived cell suspension comprises adipocytes.

Also described herein is a composition comprising (i) adipose tissue-derived cell secretions, or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of (i) and (ii), for treatment or prevention of a disease in an intensively farmed animal, wherein in said treatment or prevention the composition is administered by subcutaneous injection or intramuscular injection.

Also described herein is a pharmaceutical composition comprising (i) adipose tissue-derived cell secretions, or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of (i) and (ii), together with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. In an example the composition comprising adipose tissue-derived cell secretions further comprises adipocytes. In an example the composition is a frozen composition.

Also described herein is a kit comprising (a) a pharmaceutical composition selected from the group consisting of (i) a composition comprising adipose tissue-derived secretions, (ii) a composition comprising an adipose tissue-derived cell suspension, optionally comprising adipocytes, and (iii) a combination of (i) and (ii); and (b) instructions for use of said kit in treatment of a condition selected from the group consisting of an inflammatory disorder, a ligament injury and a tendon injury, or alleviating pain associated with an inflammatory disorder, a ligament injury or a tendon injury, wherein said treatment comprises administration of said pharmaceutical composition to a site on a subject remote from the site afflicted by the condition.

Also described herein is a kit comprising (a) a pharmaceutical composition selected from the group consisting of (i) a composition comprising adipose tissue-derived

secretions, (ii) a composition comprising an adipose tissue-derived cell suspension, optionally comprising adipocytes, and (iii) a combination of (i) and (ii); and (b) instructions for use of said kit in treatment of a joint disease or condition in a mammalian subject, wherein said treatment comprises administration of said pharmaceutical composition to a site on a subject remote from the joint afflicted by the joint disease or condition. In an example the adipose tissue-derived cell suspension, optionally comprising adipocytes, comprises aggregates of cells and or comprises pieces of adipose tissue. In an example the adipose tissue-derived cell suspension is substantially free of adipocytes. In an example the adipose tissue-derived cell suspension comprises adipocytes.

Also described herein is a kit comprising (a) a pharmaceutical composition selected from the group consisting of (i) a composition comprising adipose tissue-derived secretions, (ii) a composition comprising an adipose tissue-derived cell suspension, optionally comprising adipocytes, and (iii) a combination of (i) and (ii); and (b) instructions for use of said kit in treatment or prevention of disease in an intensively farmed animal, wherein in said treatment or prevention the composition is administered by subcutaneous injection or intramuscular injection.

In an example the kit comprises one or more frozen compositions. In an example the kit comprises instructions for combining a composition comprising adipose tissue-derived secretions and a composition comprising an adipose tissue-derived cell suspension, optionally comprising adipocytes, prior to administration of a combined composition. In an example the kit further comprises one or more injection devices, such as one or more syringes. In an example the injection device contains a composition of the kit.

Also described herein is a method of alleviating pain in a mammalian subject, the method comprising administering to the subject a pharmaceutical composition which comprises (i) adipose tissue-derived cell secretions, or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of (i) and (ii), wherein said administration to said subject is by intramuscular injection or by subcutaneous injection or by an appropriate form of administration at or near a site of the pain. In an example the pain is associated with a condition selected from the group consisting of an inflammatory disorder, a ligament injury and a tendon injury. In an example the pain is associated with osteoarthritis, stifle disease, wobblers, a tendon injury or a ligament injury. In an example the pain is associated with atopic dermatitis. In an

example the pain is associated with rheumatoid arthritis, back pain, or multiple sclerosis. In an example the pain is associated with a condition selected from the group consisting of leg weakness, lameness, arthritis, developmental diseases and bacterial infection. In an example the pain is associated with osteochondrosis (OCD). In an example the pain is associated with a burn injury. In an example the pain is neck and or shoulder pain, whiplash associated disorder, or complex regional pain syndrome. In an example the pain is back pain. In an example the pain is lower back pain. In an example the pain is pain associated with a sciatic disorder. In an example the treatment is of pain for which there is no discernable causative clinical condition. In an example the treatment is of pain for which there is no discernable causative clinical condition in the part or region of the body in which the subject experiences the pain. In an example the pain is neuropathic pain. In an example the neuropathic pain is pain for which there is no discernable causative clinical condition. In an example the appropriate form of administration is injection. In an example the appropriate form of administration is topical application. The neuropathic pain may be localised to one area of the body or it may be experienced in multiple sites of the subject's body. When experienced in multiple sites, the intensity of the pain may be similar at multiple sites or it may be different at multiple sites. In an example the neuropathic pain is neuropathic facial pain. In an example the pain is neuropathic facial pain and administration to said subject is by injection into the jaw or the gum. In an example the injection into the jaw or the gum is at the original site of the pain. In an example the pain is associated with a joint disease or joint disorder and the composition is administered to a site on said subject which is remote to said joint. In an example the adipose tissue-derived cell suspension, optionally comprising adipocytes, comprises aggregates of cells and or comprises pieces of adipose tissue.

Also described herein is use of (i) adipose tissue-derived cell secretions, or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of (i) and (ii), for the preparation of a pharmaceutical composition for use in alleviating pain in a mammalian subject, wherein the pharmaceutical composition is suitable for administration to said subject by intramuscular injection or by subcutaneous injection or by an appropriate form of administration, such as topical administration, at or near a site of the pain.

Also described herein is a composition comprising (i) adipose tissue-derived cell secretions, or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of (i) and (ii), for alleviating pain in a mammalian

subject, wherein the pharmaceutical composition is administered to said subject by intramuscular injection or by subcutaneous injection or by an appropriate form of administration, such as topical administration, at or near a site of the pain.

Also described herein is a kit comprising (a) a pharmaceutical composition selected from the group consisting of (i) a composition comprising adipose tissue-derived secretions, (ii) a composition comprising an adipose tissue-derived cell suspension, optionally comprising adipocytes, and (iii) a combination of (i) and (ii); and (b) instructions for use of said kit in alleviating pain in a mammalian subject, wherein the pharmaceutical composition is administered to said subject by intramuscular injection or by subcutaneous injection or by an appropriate form of administration, such as topical administration, at or near a site of the pain.

Also described herein is a composition comprising adipose tissue-derived cells and adipose tissue-derived cell secretions. In an example the cells are adherent cells. In an example the cells are mesenchymal stem cells. In an example the composition is a frozen composition. In an example the adipose tissue-derived cell secretions comprise clarified media from culture of adipose tissue-derived cells. In an example the adipose tissue-derived cell secretions is a concentrated preparation of media from culture of adipose tissue-derived cells. In an example the adipose tissue-derived cell secretions is a preparation concentrated between 2-fold and 20-fold. In an example the composition further comprises adipocytes. In an example the cells are progeny cells from culture of an adipose tissue-derived cell suspension. In an example the cells comprise a cell line obtained by culture of an adipose tissue-derived cell suspension. In an example the progeny cells are from multiple passaging of cells derived from an adipose tissue-derived cell suspension. In an example the multiple passaging comprises five or more passages. In an example the multiple passaging comprises ten or more passages. In an example the composition comprises cells of an adipose tissue-derived cell line which has been frozen multiple times.

Also described herein is a method for the cryopreservation of a stored cell, the method comprising combining said cell with a composition comprising cell secretions and storing said combination in a frozen state. In an example the method is for the cryopreservation of a cell line. In an example, prior to said storing, the combination is held at room temperature for up to one hour. In an example the said stored cell is an adherent cell. In an example the stored cell is a mesenchymal stem cell. In an example the stored cell is an adipose tissue-derived cell. In an example the cell line is an adipose

tissue-derived cell line. In an example the composition comprising cell secretions comprises clarified media from culture of an adipose tissue-derived cell suspension. In an example the culture of an adipose tissue-derived cell suspension is culture of progeny cells of an adipose tissue-derived cell suspension. In an example the composition comprising cell secretions comprises concentrated media from culture of an adipose tissue-derived cell suspension. In an example the composition comprising cell secretions comprises media from culture of an adipose tissue-derived cell suspension concentrated between 2-fold and 20-fold. In an example the cell line has been passaged multiple times. In an example the cell line has been passaged more than five times. In an example the cell line has been passaged more than ten times. In an example the cell line has been passaged more than fifteen times. In an example the cell line has been frozen multiple times.

It will be understood that examples described herein apply equally to any and all aspects of the invention described herein, they are simply not repeated under each aspect of the invention for the sake of brevity.

The summary of the invention described above is not limiting and other features and advantages of the invention will be apparent from the following detailed description of the preferred embodiments, as well as from the claims.

Claims

1. Use of progeny cells from culture of multiply-passaged cells from an adipose tissue-derived cell suspension and adipose tissue-derived cell secretions in the manufacture of a medicament for the treatment of a condition selected from the group consisting of an inflammatory disorder, a ligament injury and a tendon injury, or alleviating pain associated with an inflammatory disorder, a ligament injury or a tendon injury, in a mammalian subject, wherein said secretions comprise clarified and/or concentrated media from culture of adipose tissue-derived cells which have arisen as progeny cells or a cell line from prior culturing, and wherein said medicament is stored frozen under appropriate conditions and the medicament is suitable to be administered to the subject within two hours of thawing the composition.

2. The use according to claim 1, wherein the inflammatory disorder or condition is selected from the group consisting of osteoarthritis, stifle disease, wobblers, a tendon injury, a ligament injury, atopic dermatitis, rheumatoid arthritis, back pain, and multiple sclerosis.

3. The use according to claim 1, wherein the inflammatory disorder or condition is osteoarthritis.

4. The use according to claim 1 or 2, wherein the multiply-passaged cells are adherent cells.

5. The use according to any one of claims 1 to 4, wherein the multiply-passaged cells are mesenchymal stem cells.

6. The use according to any one of claims 1 to 5, wherein said multiply-passaged cells are (i) of a cell line that has been passaged more than five times, or (ii) of a cell line that has been passaged more than ten times.

7. The use according to any one of claims 1 to 6, wherein said multiply-passaged cells are of a cell line that has been frozen multiple times.

8. The use according to any one of claims 1 to 7, wherein the adipose tissue-derived cell secretions comprise clarified media from culture of adipose tissue-derived cells which have arisen as progeny cells or a cell line from prior culturing.

9. The use according to any one of claims 1 to 7, wherein the adipose tissue-derived cell secretions comprise a concentrated preparation of media from culture of adipose tissue-derived cells which have arisen as progeny cells or a cell line from prior culturing.

10. The use according to claim 9, wherein the adipose tissue-derived cell secretions is a preparation concentrated between 2-fold and 20-fold.

11. The use according to claim 10, wherein the adipose tissue-derived cell secretions is a preparation concentrated 10-fold.

12. The use according to any one of claims 1 to 11, wherein the subject is a human.

13. The use according to any one of claims 1 to 12, wherein the adipose tissue-derived cell secretions and the multiply passaged cells are derived from adipose tissue allogeneic to the recipient subject or animal.

14. The use according to any one of claims 1 to 13, wherein the medicament is to be administered to said subject by intra-articular injection.